Markets Nosedive

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

SBI Earnings

SBI Earnings

State Bank of India Q4 profit falls, shares drop.  Full Article | Related Story 

Bernanke Impact

Bernanke Impact

U.S. Fed enters delicate new phase of communication  Full Article | Column 

Subsidy Compensation

Subsidy Compensation

Government to pay state-run fuel retailers $8.1 billion in Q4 oil subsidy.  Full Article 

Ranbaxy Accusation

Ranbaxy Accusation

Daiichi Sankyo accusation "false and baseless": Singhs  Full Article 

Tata Steel Results

Tata Steel Results

Tata Steel reports loss on Europe weakness.  Full Article 

FDA Woes

FDA Woes

Wockhardt says FDA alert affects potential sales of $100 million.  Full Article 

Goldman Safeguards

Goldman Safeguards

Battle-scarred Goldman CEO unveils safeguards to avoid mistakes  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Armstrong to admit to doping in Oprah interview - report

Related Topics

Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

Lance Armstrong, founder of the LIVESTRONG foundation, takes part in a special session regarding cancer in the developing world during the Clinton Global Initiative in New York September 22, 2010. REUTERS/Lucas Jackson/Files

Lance Armstrong, founder of the LIVESTRONG foundation, takes part in a special session regarding cancer in the developing world during the Clinton Global Initiative in New York September 22, 2010.

Credit: Reuters/Lucas Jackson/Files

Sat Jan 12, 2013 8:48pm IST

REUTERS - Lance Armstrong plans to admit to doping throughout his career in an interview with Oprah Winfrey next week, the American cyclist's first interview since being stripped of his seven Tour de France titles, USA Today reported on Saturday.

But Armstrong, 41, likely will not offer great detail about specific cases and events, the paper said, citing an unidentified source with knowledge of the situation.

The interview is scheduled to tape on Monday at Armstrong's home in Austin, Texas, and set to air on Thursday on the Oprah Winfrey Network.

Such an admission would mark a major reversal for the famed cyclist. Armstrong has always vehemently denied using performance-enhancing drugs and has never been proven to have tested positive.

But an October report from the U.S. anti-doping body USADA cited Armstrong's involvement in what it characterized as the "most sophisticated, professionalized and successful doping program that sport has ever seen," involving anabolic steroids, human growth hormone, blood transfusions and other doping.

Less than two weeks later, Armstrong's seven Tour de France victories were nullified and he was banned from cycling for life after the International Cycling Union ratified the USADA's sanctions against him.

The New York Times reported last week that Armstrong was considering an admission of using banned drugs with the hopes of persuading anti-doping officials to allow him to resume competition in athletic events that adhere to the World Anti-Doping Code.

Another motivation might be to keep the scandal from hurting Livestrong, the cancer-support charity he founded in 1997, USA Today said on Saturday. Armstrong, a survivor of testicular cancer, stepped down as a board member in November.

Armstrong's planned admission, however, carries the risk of getting him sued or held reliable by those who believe he defrauded them by lying about his use of drugs, the paper reported.

(Reporting by Colleen Jenkins; Editing By Doina Chiacu)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.